CAR-T Followed by Bispecific Antibodies

Recruiting
18 years - 99 years
All
Phase 2
40 participants needed
1 Location

Brief description of study

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Large B-cell Lymphoma
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, Age 18 or older Life expectancy of at least 12 weeks, History of relapsed or refractory DLBCL, HGBCL, PMBCL or tFL who have relapsed after or failed to respond to at least two prior standard systemic treatment regimens

Updated on 04 Aug 2024. Study ID: 844799

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Race
Select race of your choice
Ethnicity
Select ethinicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center